Telomere Length and Telomerase Upregulation
UK research group confirmed Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.
[1]A synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG), developed within the Khavinson short peptide bioregulator program as a synthetic analog of natural pineal peptide preparations. One of the most extensively studied short peptide bioregulators, with the deepest claims around longevity, telomere biology, and circadian regulation.
At a glance
- Type
- Synthetic tetrapeptide, sequence Ala-Glu-Asp-Gly (AEDG)
- Origin
- Khavinson short peptide bioregulator program; synthetic analog of natural pineal peptide preparations
- Focus
- Longevity science, telomere biology, circadian regulation
- Routes
- Subcutaneous or intramuscular
- Regulatory
- Not FDA approved; regulatory status may vary by jurisdiction
What the research supports
Epitalon has the deepest published evidence base of any Khavinson short peptide bioregulator, with recent Western validation of telomere biology claims.
Antioxidant and Diabetic Retinopathy
Antioxidant tetrapeptide Epitalon enhanced delayed wound healing in an in vitro model of diabetic retinopathy; reduced intracellular ROS and restored antioxidant gene expression.
[2]Therapeutic Peptides in Gerontology
Reviewed as the flagship longevity peptide alongside other Khavinson bioregulators in a comprehensive gerontology review.
[3]Pineal Gland Modulation
Modulates pineal gland function and melatonin output in animal models; lifespan extension data across multiple animal studies.
Summary of key findings
Telomerase Upregulation Validated
2025 Western data confirmed Epitalon increases telomere length via telomerase upregulation in human cell lines. This represents the key Western validation of a previously Russian-dominated claim.
Antioxidant Activity
Reduces intracellular ROS and restores antioxidant gene expression with documented effects in diabetic retinopathy in vitro models.
Longevity Flagship
Most published Khavinson short peptide bioregulator; biologically plausible mechanism with caveats on lifespan claims. Human lifespan extension data does not yet exist.
Cancer History Caution
Telomerase upregulation creates a theoretical caution in patients with active or recent malignancy. Position carefully with all patients.
Dosing guide
From published protocols. Licensed provider supervision assumed throughout.
- Subcutaneous Protocol
- 5 to 10 mg daily for 10 to 20 days per cycle. 10 mg is the standard. Administer AM on empty stomach.
- Cycling Tradition
- Khavinson tradition: 1 to 2 courses per year, typically spring and fall. 20-bottle full-bottle daily cycles also used.
- Intramuscular Alternative
- Same dose range as subcutaneous. Either parenteral route is acceptable depending on patient preference.
- Source Verification
- Pharmacy identity and purity testing important. Compounded supply varies; verify before administration.
Vial reference
Units are for a U-100 insulin syringe (100 units = 1 mL), computed from the vial concentration.
| Vial | Dose range | Units per dose | Frequency | Notes |
|---|---|---|---|---|
| Epitalon (clinical) | 10 mg | Per protocol | Daily for 10 days, twice per year | AM empty stomach. SC. |
| Epithalon 10 mg / 1 mL | 10 mg | 100 units | 20-bottle cycle, daily for 20 days | 0.1 mg per unit. 2x to 3x annually. |
Reference ranges as published in the source protocol document, not a prescription. To work out the draw for a specific vial and dose, use the Peptide Calculator.
Bottom line
Epithalon is the flagship peptide of the longevity space, with the most published research of any Khavinson short peptide bioregulator. Recent 2025 data from a UK research group confirmed that Epitalon increases telomere length in human cell lines through telomerase upregulation, the key Western validation of a previously Russian-dominated claim.
Position carefully with patients: longevity claims are biologically plausible and supported by mechanistic data, but human lifespan extension data does not exist and cannot be claimed. The telomerase upregulation mechanism creates a theoretical caution in patients with active or recent malignancy. Practical protocols typically run 10 to 20 day courses twice a year. Pairs well with NAD precursors, glutathione, and other Khavinson bioregulators (Cartalax, Cardigen, Pinealon).
Telomere Maintenance
Telomerase upregulation validated in human cell lines (2025).
Antioxidant Support
ROS reduction and antioxidant gene expression restoration.
Longevity Protocol Foundation
Most studied Khavinson bioregulator with seasonal cycling tradition.
References
Citations sourced from PubMed and verified against the PubMed record.
- 1Al-Dulaimi et al., 2025 Epitalon increases telomere length in human cell lines
- 2Gatta et al., 2025 Antioxidant Tetrapeptide Epitalon in diabetic retinopathy wound healing
- 3Mavrych et al., 2026 Therapeutic peptides in gerontology
- 4Rahman et al., 2026 Therapeutic Peptides in Orthopaedics
Regulatory status, cautions and contraindications
Regulatory Status
Epithalon is not FDA approved. All use is outside the scope of FDA-regulated indications. Regulatory status may vary by jurisdiction.
Contraindication Note
Active or recent malignancy: relative contraindication due to telomerase upregulation mechanism. Assess individual patient risk before prescribing.
Source Verification
Source verification is important. Pharmacy identity testing is recommended. Compounded peptide supply quality varies significantly across providers.
Legal disclaimer
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
This peptide overview is for informational purposes only and does not constitute medical advice. The information provided here is not intended to diagnose, treat, cure, or prevent any disease. Peptide therapies should only be used under the guidance of a licensed healthcare provider, who can assess individual health needs and determine appropriate dosing and administration.
Always consult your healthcare provider before starting any new treatment, as misuse or improper dosing may lead to adverse effects. The efficacy and safety of peptide therapies have not been fully established in all cases, and ongoing medical supervision is essential.